Inventiva S.A.
IVA
주식 순위
#10488
Inventiva S.A. is a biopharmaceutical firm currently in the clinical... Inventiva S.A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments. Their primary drug candidate, Lanifibranor, has successfully concluded Phase IIb clinical trials for the management of NASH. Furthermore, the company is advancing Odiparcil, a compound that has finished Phase IIa clinical testing specifically for treating the MPS VI subtype. Beyond these, Inventiva maintains a development pipeline featuring several early-stage projects targeting oncology and other medical conditions. Strategic partnerships are in place with AbbVie to address autoimmune diseases, and with Boehringer Ingelheim International GmbH for innovating therapies for idiopathic pulmonary fibrosis. Established in 2011, Inventiva S.A. operates from its headquarters in Daix, France.
주가
$3.30
시가총액
$778.94M
변동 (1일)
1.65%
변동 (1년)
-17.79%
국가
FR
거래 Inventiva S.A. (IVA)
카테고리
Healthcare
의 시가총액 Inventiva S.A.(IVA)
시가총액: $778.94M
October 2026 기준으로 Inventiva S.A.의 시가총액은 $778.94M입니다. 이는 당사 데이터에 따르면 Inventiva S.A.이 세계에서 10488th번째로 가치 있는 기업임을 의미합니다. 시가총액은 상장된 회사의 발행 주식 총 시장 가치를 의미하며, 일반적으로 회사의 가치를 측정하는 데 사용됩니다.
2021부터 2026까지 Inventiva S.A.의 시가총액 기록
